Edition:
United Kingdom

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.35USD
8:59pm GMT
Change (% chg)

$0.01 (+0.75%)
Prev Close
$1.34
Open
$1.31
Day's High
$1.39
Day's Low
$1.30
Volume
12,228
Avg. Vol
19,192
52-wk High
$2.37
52-wk Low
$1.17

Latest Key Developments (Source: Significant Developments)

Veru Announces Bioavailability And Bioequivalence Clinical Trial For Tadalafil And Finasteride Combination Tablet
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Veru Inc ::VERU ANNOUNCES SUCCESSFUL BIOAVAILABILITY AND BIOEQUIVALENCE CLINICAL TRIAL FOR TADALAFIL AND FINASTERIDE COMBINATION TABLET FOR BENIGN PROSTATIC HYPERPLASIA.VERU INC - HAS ALSO REQUESTED PRE-NDA MEETING WITH FDA, AND ANTICIPATES SUBMITTING NDA UNDER 505(B)(2) REGULATORY PATHWAY IN H2 2019.VERU INC - STABILITY TESTING OF COMMERCIALLY MANUFACTURED BATCHES OF TAD-FIN COMBINATION TABLET REQUIRED FOR SUBMISSION OF NDA IS IN PROGRESS.  Full Article

Veru Reports Q4 Loss Per Share Of $0.14
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Veru Inc ::VERU REPORTS STRONG NET REVENUES AND GROSS PROFIT FOR FISCAL 2018 FOURTH-QUARTER.Q4 LOSS PER SHARE $0.14.Q4 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.Q4 REVENUE ROSE 41 PERCENT TO $5.2 MILLION.Q4 REVENUE ESTIMATE $6.7 MILLION -- REFINITIV IBES DATA.  Full Article

Veru Announces Proposed Public Offering Of Common Stock
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Veru Inc ::VERU ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.VERU INC - IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET CONDITIONS, SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Veru Has Successful Pre-Ind Meeting With FDA For Veru-111 Next Generation Novel Oral Anti-Tubulin Therapy For Metastatic Prostate Cancer
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Veru Inc ::VERU HAS SUCCESSFUL PRE-IND MEETING WITH FDA FOR VERU-111 NEXT GENERATION NOVEL ORAL ANTI-TUBULIN THERAPY FOR METASTATIC PROSTATE CANCER.VERU INC - FDA AGREED WITH VERU'S PLANS FOR A PHASE 1/2 CLINICAL TRIAL FOR VERU-111.VERU INC - EXPECT TO HAVE AN EARLY ASSESSMENT OF SAFETY AND EFFICACY OF VERU-111 BY EARLY PART OF 2019.VERU INC - FDA AGREED THAT AN IND FOR VERU-111 MAY BE SUBMITTED.  Full Article

Veru To Start Phase 2 Trial To Test Its Treatment For Side Effect Of Prostate Cancer Therapy
Tuesday, 12 Jun 2018 

June 12 (Reuters) - Veru Inc ::VERU TO START PHASE 2 TRIAL TO EVALUATE CIS-CLOMIPHENE CITRATE TO TREAT HOT FLASHES CAUSED BY ADVANCED PROSTATE CANCER THERAPY.VERU INC - SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S. FDA FOR VERU-944.VERU-EXPECT THIS SUMMER TO COMMENCE ENROLLING ABOUT 120 PATIENTS INTO PHASE 2 CLINICAL STUDY.VERU INC - U.S. PATENT ISSUED FOR VERU-944, EXPIRING 2035.  Full Article

Veru Inc - On Jan 4, 2018, Daniel Haines, CFO, Informed Co That He Was Resigning ‍​
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Veru Inc ::VERU INC - ON JAN 4, 2018, DANIEL HAINES, CFO, INFORMED CO THAT HE WAS RESIGNING ‍​.VERU SAYS ‍HAINES' DUTIES AS CFO WERE ASSIGNED EFFECTIVE JAN 4, 2018 TO MICHELE GRECO​ - SEC FILING.  Full Article

Veru reports Q4 Loss Per Share $0.10
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $3.7 MILLION VERSUS $3.6 MILLION.  Full Article

Veru Acquires Novel Proprietary Formulation For Overactive Bladder
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Veru Inc ::VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER.VERU PLANS TO BEGIN SOLIFENACIN DRG BIOEQUIVALENCE STUDY IN 2018 AND TO FILE NDA IN 2019.‍UNDER TERMS OF AGREEMENT WITH CAMARGO, VERU PAID AN UNDISCLOSED UPFRONT FEE TO ACQUIRE ASSET​.UNDER TERMS, VERU TO PAY UNDISCLOSED MILESTONE FEES UPON SUCCESSFUL CLINICAL DEVELOPMENT, LOW SINGLE DIGIT ROYALTY UPON COMMERCIAL SALES​.FDA ‍CONFIRMED IN A MEETING WITH CO THAT REGULATORY APPROVAL FOR SOLIFENACIN DRG WILL REQUIRE A SINGLE BIOEQUIVALENCE STUDY​.  Full Article

Veru announces Tamsulosin drs bioequivalence clinical trial results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Veru Inc :Veru announces Tamsulosin Drs bioequivalence clinical trial results.Veru Inc - ‍Expected timing of additional formulation adjustment should allow us to remain on track for a pre-NDA meeting in early 2018​.  Full Article

Veru files for mixed shelf of up to $50 million
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Veru Inc :Files for mixed shelf of up to $50 million - SEC filing‍​.  Full Article